U.S. markets closed
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • Dow 30

    33,874.24
    -71.34 (-0.21%)
     
  • Nasdaq

    14,271.73
    +18.46 (+0.13%)
     
  • Russell 2000

    2,303.47
    +7.52 (+0.33%)
     
  • Crude Oil

    73.28
    +0.20 (+0.27%)
     
  • Gold

    1,778.70
    -4.70 (-0.26%)
     
  • Silver

    25.93
    -0.18 (-0.67%)
     
  • EUR/USD

    1.1932
    -0.0011 (-0.10%)
     
  • 10-Yr Bond

    1.4870
    +0.0150 (+1.02%)
     
  • GBP/USD

    1.3965
    +0.0018 (+0.13%)
     
  • USD/JPY

    110.9700
    +0.3350 (+0.30%)
     
  • BTC-USD

    33,374.69
    +872.66 (+2.68%)
     
  • CMC Crypto 200

    800.68
    -9.51 (-1.17%)
     
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • Nikkei 225

    28,874.89
    -9.24 (-0.03%)
     

Amarin Stock Is Trading Higher After EU Approval For Icosapent Ethyl

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • The European Commission (EC) has approved the marketing authorization application for Amarin Corporation Plc's (NASDAQ: AMRN) Vazkepa (icosapent ethyl) for cardiovascular risk reduction.

  • The approval covers reducing the risk of cardiovascular events in high-risk, statin-treated adult patients who have elevated triglycerides and either established cardiovascular disease or diabetes and at least one additional cardiovascular risk factor.

  • Amarin's icosapent ethyl was approved for cardiovascular risk reduction by the FDA in December 2019 and marketed in the U.S. under the brand name, Vascepa.

  • Yesterday, Amarin's Canadian partner, HLS Therapeutics Inc, announced the Canadian Cardiovascular Society recommended using icosapent ethyl to lower the risk of cardiovascular events.

  • Price Action: AMRN shares are up 4.6% at $6.41 in premarket trading on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.